ECSP088384A - Derivados de triazol como inhibidores de 11-beta-hidroxiesteroide-deshidrogenasa-1 - Google Patents

Derivados de triazol como inhibidores de 11-beta-hidroxiesteroide-deshidrogenasa-1

Info

Publication number
ECSP088384A
ECSP088384A EC2008008384A ECSP088384A ECSP088384A EC SP088384 A ECSP088384 A EC SP088384A EC 2008008384 A EC2008008384 A EC 2008008384A EC SP088384 A ECSP088384 A EC SP088384A EC SP088384 A ECSP088384 A EC SP088384A
Authority
EC
Ecuador
Prior art keywords
inhibitors
hydroxiesteroid
dehydrogenasa
beta
triazol derivatives
Prior art date
Application number
EC2008008384A
Other languages
English (en)
Inventor
Sherman T Waddell
Xin Gu
James M Balkovec
Nancy J Kevin
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Publication of ECSP088384A publication Critical patent/ECSP088384A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/08—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing alicyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Abstract

Los derivados triazol de fórmula estructural I son inhibidores selectivos de la 11ß-hidroxiesteroide-dehidrogenasa-1. Los compuestos son útiles para el tratamiento de diabetes, tal como diabetes no dependiente de la insulina (NIDDM), hiperglucemia, obesidad, resistencia a insulina, dislipidemia, hiperlipidemia, hipertensión, síndrome metabólico y otros síntomas asociados con NIDDM.
EC2008008384A 2005-10-20 2008-04-17 Derivados de triazol como inhibidores de 11-beta-hidroxiesteroide-deshidrogenasa-1 ECSP088384A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US72872305P 2005-10-20 2005-10-20

Publications (1)

Publication Number Publication Date
ECSP088384A true ECSP088384A (es) 2008-05-30

Family

ID=37963190

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2008008384A ECSP088384A (es) 2005-10-20 2008-04-17 Derivados de triazol como inhibidores de 11-beta-hidroxiesteroide-deshidrogenasa-1

Country Status (18)

Country Link
US (1) US7981910B2 (es)
EP (1) EP1940393B1 (es)
JP (1) JP5036722B2 (es)
KR (1) KR20080059236A (es)
CN (2) CN103724335A (es)
AU (1) AU2006304434B2 (es)
BR (1) BRPI0617501A2 (es)
CA (1) CA2625871C (es)
CR (1) CR9931A (es)
EC (1) ECSP088384A (es)
IL (1) IL190436A0 (es)
MA (1) MA30201B1 (es)
NI (1) NI200800069A (es)
NO (1) NO20082278L (es)
RU (1) RU2008119842A (es)
SV (1) SV2009002876A (es)
WO (1) WO2007047625A2 (es)
ZA (1) ZA200802104B (es)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7834178B2 (en) 2006-03-01 2010-11-16 Bristol-Myers Squibb Company Triazine 11-beta hydroxysteroid dehydrogenase type 1 inhibitors
AU2007283113A1 (en) 2006-08-08 2008-02-14 Sanofi-Aventis Arylaminoaryl-alkyl-substituted imidazolidine-2,4-diones, processes for preparing them, medicaments comprising these compounds, and their use
US7727978B2 (en) 2006-08-24 2010-06-01 Bristol-Myers Squibb Company Cyclic 11-beta hydroxysteroid dehydrogenase type I inhibitors
CN101663033B (zh) * 2007-04-18 2013-01-16 默沙东公司 作为smo拮抗剂的三唑衍生物
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
UY31968A (es) 2008-07-09 2010-01-29 Sanofi Aventis Nuevos derivados heterocíclicos, sus procesos para su preparación, y sus usos terapéuticos
WO2010068601A1 (en) 2008-12-08 2010-06-17 Sanofi-Aventis A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof
FR2942797B1 (fr) * 2009-03-03 2011-04-29 Pf Medicament Derives de benzothiazines, leur preparation et leur application a titre de medicaments
ES2350077B1 (es) 2009-06-04 2011-11-04 Laboratorios Salvat, S.A. Compuestos inhibidores de 11beta-hidroxiesteroide deshidrogenasa de tipo 1.
CA2771278A1 (en) 2009-08-26 2011-03-03 Sanofi Novel crystalline heteroaromatic fluoroglycoside hydrates, pharmaceuticals comprising these compounds and their use
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
EP2582709B1 (de) 2010-06-18 2018-01-24 Sanofi Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
US8828994B2 (en) 2011-03-08 2014-09-09 Sanofi Di- and tri-substituted oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
US8871758B2 (en) 2011-03-08 2014-10-28 Sanofi Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
WO2012120053A1 (de) 2011-03-08 2012-09-13 Sanofi Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120052A1 (de) 2011-03-08 2012-09-13 Sanofi Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
EP2683699B1 (de) 2011-03-08 2015-06-24 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP2760862B1 (en) 2011-09-27 2015-10-21 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
CN104910083A (zh) * 2015-07-13 2015-09-16 佛山市赛维斯医药科技有限公司 烷氧苯基三氮唑亚砜类11β-HSD1抑制剂、制备方法及其用途
CN105001170A (zh) * 2015-07-13 2015-10-28 佛山市赛维斯医药科技有限公司 末端腈基取代的三氮唑亚砜类化合物、其制备方法及其用途
CN104961696A (zh) * 2015-07-13 2015-10-07 佛山市赛维斯医药科技有限公司 一类卤苯三氮唑亚砜类11β-HSD1抑制剂、制备方法及其用途
CN104910084A (zh) * 2015-07-13 2015-09-16 佛山市赛维斯医药科技有限公司 末端胺基取代的三氮唑亚砜类化合物、其制备方法及其用途
CN105001171A (zh) * 2015-07-13 2015-10-28 佛山市赛维斯医药科技有限公司 一类硝基苯三氮唑亚砜类11β-HSD1抑制剂及其用途
CN105017170A (zh) * 2015-07-13 2015-11-04 佛山市赛维斯医药科技有限公司 一类腈基苯三氮唑亚砜类11β-HSD1抑制剂及其用途
CN104961697A (zh) * 2015-07-13 2015-10-07 佛山市赛维斯医药科技有限公司 末端卤素取代的三氮唑亚砜类化合物、其制备方法及其用途
CN104987313A (zh) * 2015-07-13 2015-10-21 佛山市赛维斯医药科技有限公司 一类末端取代的三氮唑亚砜类化合物、其制备方法及其用途
CN104987312A (zh) * 2015-07-13 2015-10-21 佛山市赛维斯医药科技有限公司 一类胺基苯三氮唑亚砜类11β-HSD1抑制剂及其用途
CN104974103A (zh) * 2015-07-14 2015-10-14 佛山市赛维斯医药科技有限公司 一类含苯并异恶唑和烷氧苯基类结构的化合物及其用途
CN104926745A (zh) * 2015-07-14 2015-09-23 佛山市赛维斯医药科技有限公司 含苯并异恶唑和末端卤代苄基类结构的化合物及其用途
CN105001152A (zh) * 2015-07-19 2015-10-28 佛山市赛维斯医药科技有限公司 一类二甲胺基二吡啶叔醇结构的11β-HSD1抑制剂及其用途
CN105017135A (zh) * 2015-07-19 2015-11-04 佛山市赛维斯医药科技有限公司 一类二吡啶叔醇结构的11β-HSD1抑制剂、制备方法及其用途
TWI802591B (zh) * 2017-09-14 2023-05-21 日商第一三共股份有限公司 具有環狀構造的化合物
US11917514B2 (en) 2018-08-14 2024-02-27 Rapidsos, Inc. Systems and methods for intelligently managing multimedia for emergency response

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO2397B1 (en) * 2002-12-20 2007-06-17 ميرك شارب اند دوم كوربوريشن Terazol derivatives as beta-hydroxy steroid dihydrogenase-1 inhibitors

Also Published As

Publication number Publication date
JP5036722B2 (ja) 2012-09-26
JP2009512704A (ja) 2009-03-26
CN103724335A (zh) 2014-04-16
KR20080059236A (ko) 2008-06-26
AU2006304434A1 (en) 2007-04-26
SV2009002876A (es) 2009-02-19
MA30201B1 (fr) 2009-02-02
WO2007047625A2 (en) 2007-04-26
US20090258913A1 (en) 2009-10-15
CA2625871A1 (en) 2007-04-26
RU2008119842A (ru) 2009-12-10
WO2007047625A3 (en) 2007-10-11
US7981910B2 (en) 2011-07-19
BRPI0617501A2 (pt) 2011-07-26
NO20082278L (no) 2008-07-17
AU2006304434B2 (en) 2012-04-05
CR9931A (es) 2008-08-21
EP1940393A2 (en) 2008-07-09
EP1940393A4 (en) 2008-12-17
CN101291672A (zh) 2008-10-22
ZA200802104B (en) 2009-08-26
CA2625871C (en) 2014-07-08
NI200800069A (es) 2008-06-25
IL190436A0 (en) 2008-12-29
EP1940393B1 (en) 2012-07-25

Similar Documents

Publication Publication Date Title
ECSP088384A (es) Derivados de triazol como inhibidores de 11-beta-hidroxiesteroide-deshidrogenasa-1
ECSP055860A (es) Derivados de triazol como inhibidores de 11-beta-hidroxiesteroide deshidrogenasa 1
EP1797034A4 (en) SULFONYL COMPOUNDS AS AN INHIBITORS OF 11-BETA-HYDROXYSTEROIDDEHYDROGENASE-1
ATE476425T1 (de) Triazolderivate als inhibitoren von 11-beta- hydroxysteroid-dehydrogenase-1
WO2007087150A3 (en) Triazole derivatives as inhibitors of 11-beta-hydroxysteroid dehydrogenase-1
WO2005016877A3 (en) Pyrazole carboxamides as inhibitors of 11-beta-hydroxysteroid dehydrogenase-1
ECSP045482A (es) Inhibidores de la 11-beta-hydroxiesteroide deshidrogenasa 1 para el tratamiento de la diabetes, obesidad y dislipidemia
CL2011002697A1 (es) Compuestos derivados de 3-[4-(oxo-dihidropiridin)bencil]-1,3-oxazin-ona hidratados, inhibidores 11beta-hsd1; composicion farmaceutica que los comprende; y su uso en el tratamiento de la diabetes
TW200612947A (en) Organic compounds
CL2009001189A1 (es) Compuestos derivados de pirazol, diazol y triazol sustituidos, exceptuando imidazol, antagonistas del receptor de glucagon; composicion farmaceutica; y su uso en el tratamiento o retraso del comienzo de la diabetes mellitus tipo 2, tratamiento de la hiperglucemia y baja tolerancia a la glucosa, entre otras enfermedades.
CY1110753T1 (el) Αναστολεις της 11-βητα-υδροξυστεροειδους αφυδρογονασης i
DK2021337T3 (da) Inhibitorer af 11-beta-hydroxysteroid-dehydrogenase-1
BRPI0615705A2 (pt) processo para preparar um composto, e, composto
CL2008001049A1 (es) Compuestos derivados de benzamidas sustituidas; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de la diabetes, intolerancia a la glucosa, dislipidemia, hipertension, obesidad.
CL2009000889A1 (es) Compuestos derivados de 2-oxo-2,5-dihidro pirrol propionamida, activadores de glucoquinasa; procedimiento de preparacion; composicion farmaceutica que comprende a dichos compestos; y su uso en el tratamiento de diabetes mellitus.
ATE557024T1 (de) Piperidinverbindungen als gpcr-agonisten
MX2009003716A (es) Antidepresivo, neuroprotector, inhibidor de deposito de amiloide beta o agente de retardo del envejecimiento que contiene un compuesto heterociclico con estructura especifica.
CL2007002888A1 (es) Compuestos derivados de n-metansulfonilamino amidas, inhibidores de metaloproteasas de matriz; composicion farmaceutica; y uso para el tratamiento de un trastorno de proliferacion celular.
CY1125273T1 (el) Ανταγωνιστης υποδοχεα glp-1 για χρηση στη θεραπεια συγγενους υπερινσουλινισμου
DK1954668T3 (da) Homo- og heterocykliske forbindelser, der er egnede som CETP-inhibitorer
ECSP10010168A (es) Benzotiazolas como moduladores del receptor de ghrelina
DOP2003000795A (es) Derivados de triazol como inhibidores de ii-beta- hidroxiesteroide deshidrogenasa-1
DOP2003000658A (es) Inhibidores de la 11-beta-hydroxiesteroide deshidrogenasa 1 para la elaboracion de tratamiento de la diabetes, obesidad y dislipidemia
GT200800043A (es) Derivados de triazol como inhibidores de 11-beta - hidroxiesteroide - deshidrogenasa - 1
UA96967C2 (en) Piperidine gpcr agonists